Enovis (Enovis) Risk Assessment

View and export this data going back to 2008. Start your Free Trial

What is Enovis Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Enovis is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Enovis's Risk Assessment

For the Specialty Industrial Machinery subindustry, Enovis's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enovis's Risk Assessment Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Enovis's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Enovis's Risk Assessment falls into.

Enovis (NYSE:ENOV) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Enovis Risk Assessment Related Terms

Thank you for viewing the detailed overview of Enovis's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Enovis (Enovis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Enovis Corp (NYSE:ENOV) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

C520:Germany

Address

2711 Centerville Road, Suite 400, Wilmington, DE, USA, 19808

Website

https://www.enovis.com

Enovis Corp is a medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows by manufacturing and distributing high-quality medical devices with a broad range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy.. The company conducts its operations through two operating segments: Prevention & Recovery ("P&R") and Reconstructive ("Recon"). It generates majority revenue form Prevention & Recovery segment.

Executives

John Kleckner	officer: Principal Accounting Officer	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Berry Phillip Benjamin (ben)	officer: SVP, Chief Financial Officer	2711 CENTERVILLE ROAD SUITE 400, WILMINGTON DE 19808
Rajiv Vinnakota	director	8730 STONY POINT PARKWAY, SUITE 150, RICHMOND VA 23235
A Clayton Perfall	director
Brady Shirley	officer: EVP, Colfax, Pres. & CEO, DJO	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Patricia A Lang	officer: SVP, Chief HR Officer	C/O DIEBOLD NIXDORF, INCORPORATED, 5995 MAYFAIR ROAD, NORTH CANTON OH 44720
Bradley J Tandy	officer: SVP, General Counsel	P.O. BOX 587, 56 E. BELL DRIVE, WARSAW IN 46580
Daniel A Pryor	officer: SVP??Strategy & Business Deve.	DANAHER CORP, 2099 PENNSYLVANIA AVE NW 12TH FL, WASHINGTON DC 20006
Matthew L. Trerotola	director, officer: President & CEO	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Christopher M Hix	officer: SVP, Chief Financial Officer	2160 SATELLITE BLVD., SUITE 200, DULUTH GA 30097
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Christine Ortiz	director	1200 ABERNATHY ROAD, NE, SUITE 1200, ATLANTA GA 30328
Angela S Lalor	director	3M CENTER, BLDG. 0220-09-E-02, ST PAUL MN 55144 1000
Shyam Kambeyanda	officer: ESAB President and SVP, Colfax	2711 CENTERVILLE ROAD, SUITE 400, WILMINGTON DE 19808
Douglas J. Pitts	officer: Controller, PAO	100 MATSONFORD ROAD, RADNOR PA 19087